Rik J Verheijden

11PUBLICATIONS
21CO-AUTHORS
AutoimmunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 23, 2026
Author Correction: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova

|Nov 18, 2025
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.

Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova

|Nov 15, 2024
Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story.

Rik J Verheijden, Jolien S de Groot, Babs O Fabriek

|Aug 07, 2024
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.

Rik J Verheijden, Jolien S de Groot, Babs O Fabriek

|Jul 05, 2024
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.

Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs

Pageof 2